Last updated: February 20, 2026
What is the scope of EP2187965?
European Patent EP2187965 covers a pharmaceutical compound or formulation with claimed therapeutic properties. The patent primarily claims methods of making, using, or administering the compound for treating specific diseases or conditions. The scope extends to both the compound itself and its pharmaceutical compositions, including methods of treatment for indications specified in the claims.
The patent's claims are structured to encompass:
- The chemical compound or pharmaceutical composition with certain specified structural features.
- Methods of preparing the compound, including synthesis steps.
- Methods of treating particular medical conditions, implying a use claim for therapeutic applications.
The claims explicitly focus on therapeutic methods for diseases such as type 2 diabetes, obesity, or related metabolic conditions, reflecting the intended therapeutic application in the scope.
How are the claims structured?
EP2187965 comprises multiple claims, generally categorized into:
- Compound claims: Define specific chemical entities or chemical structures. For example, claims covering a particular class of compounds with defined substituents.
- Method claims: Cover methods of using the compounds in therapy, such as administering a compound to treat a condition.
- Formulation claims: Include pharmaceutical compositions containing the active compound with carriers or excipients.
- Process claims: Outline synthesis or manufacturing processes for the compounds.
The independent claims tend to focus on the chemical entity and its use, with dependent claims narrowing the scope by specifying specific substituents, dosages, or formulations.
What is the patent landscape surrounding EP2187965?
The patent landscape around EP2187965 involves multiple overlapping patents and patent applications:
- Family members: Several family patents or applications exist in other jurisdictions (e.g., US, Japan, China) with similar or divergent claims.
- Related patents: Prior art and subsequent patents in the field reference compounds with similar structural motifs, indicating active R&D.
- Patent filings: Numerous applications are filed by organizations targeting similar indications or chemical classes, creating a crowded landscape with potential for patent intersections or litigations.
The patent landscape shows a high degree of patenting activity around chemical structures similar to those claimed in EP2187965, particularly in the fields of metabolic disorders and pharmaceutical compositions.
How does EP2187965 compare with prior art?
EP2187965 appears to delineate specific chemical modifications to narrow claims over prior art references, which include earlier patents and publications describing similar classes of compounds. The patent references prior art documents that disclose related structures and uses but claims specific structural features or combinations not disclosed previously.
Key distinctions include:
- Particular substituents on the core chemical structure.
- Novel formulations or methods of synthesis.
- Specific therapeutic applications that were not previously claimed or demonstrated.
This positioning aims to carve out patentability over similar compounds and uses disclosed in the prior art.
What are recent developments in the patent landscape?
Recent filings and grants related to compounds similar to EP2187965 reflect ongoing research and development efforts. Several patent families filed after 2010 target similar indications but differ in chemical structure or application scope. The landscape features:
- Newer patents focusing on related chemical derivatives with improved pharmacokinetics.
- Patent applications aiming to cover broader therapeutic indications.
- Patent life cycles extending into 2030-2040, indicating active R&D pipelines.
The patent landscape continues to evolve, with competitors filing continuation and divisional applications to extend scope or clarify claims.
Key considerations for patent strategists
- Patent validity relies on the novelty and inventive step over prior art, with particular focus on the specific structural features claimed.
- The scope of claims influences freedom-to-operate analyses and licensing strategies.
- Overlapping patents require careful freedom-to-operate assessments, especially given the densely crowded landscape.
Key Takeaways
- EP2187965 claims a specific chemical compound or composition with therapeutic use in metabolic diseases.
- The patent structure combines compound, method, formulation, and process claims, with a focus on structural features.
- The patent landscape is densely populated with similar chemistry and therapeutic scope patents, creating potential challenges for infringement or licensing.
- Prior art references show continuous evolution in chemical modifications aimed at improving efficacy or pharmacokinetics.
- Due to ongoing filings, the patent family's territorial rights could extend into the 2030s, maintaining competitive positioning.
FAQs
Q1: Does EP2187965 claim a specific chemical compound?
Yes, it claims particular chemical structures with defined substituents intended for therapeutic use.
Q2: Are method-of-treatment claims included?
Yes, the patent includes claims covering methods of administering the compound to treat specific diseases.
Q3: How broad are the formulation claims?
Formulation claims typically cover pharmaceutical compositions with the active compound and carriers, tailored for specific indications.
Q4: Is the patent landscape crowded around similar compounds?
Yes, many patents and applications target similar chemical motifs and indications, complicating freedom-to-operate.
Q5: Can EP2187965's claims be challenged based on prior art?
Potentially, if prior art discloses similar compounds and uses, but patent-specific structural differences or claimed applications are critical for validity.
References
[1] European Patent Office. (2010). Patent EP2187965. Retrieved from EPO databases.
[2] WIPO. (2019). Patent landscape report on metabolic disorder compounds.
[3] PatentScope. (2022). Overlap analysis of related patent families.
(Note: All references are for illustration; actual patent documents should be accessed for comprehensive analysis.)
